Cargando…

IMMU-09. DISSECTING THE INTERPLAY BETWEEN THE ENDOGENOUS IMMUNE RESPONSE AND ONCOLYTIC VIRUS THERAPY IN PEDIATRIC BRAIN TUMORS

Oncolytic virus (OV) elicits an antitumor immune response in addition to tumor-cell killing. However, it is unknown if a pre-existing antitumor immune response aids or hinders OV therapy. To study the interplay between the endogenous immune response and OV we profiled tumors from immunocompetent int...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoare, Owen, Jung, Jangham, Inagaki, Akihito, Yu, Bohyeon, Collins, Sara, Chuntova, Polly, Barcova, Maria, Patel, Trishna, Kasahara, Noriyuki, Müller, Sabine, Diaz, Aaron
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10259983/
http://dx.doi.org/10.1093/neuonc/noad073.196
_version_ 1785057760684015616
author Hoare, Owen
Jung, Jangham
Inagaki, Akihito
Yu, Bohyeon
Collins, Sara
Chuntova, Polly
Barcova, Maria
Patel, Trishna
Kasahara, Noriyuki
Müller, Sabine
Diaz, Aaron
author_facet Hoare, Owen
Jung, Jangham
Inagaki, Akihito
Yu, Bohyeon
Collins, Sara
Chuntova, Polly
Barcova, Maria
Patel, Trishna
Kasahara, Noriyuki
Müller, Sabine
Diaz, Aaron
author_sort Hoare, Owen
collection PubMed
description Oncolytic virus (OV) elicits an antitumor immune response in addition to tumor-cell killing. However, it is unknown if a pre-existing antitumor immune response aids or hinders OV therapy. To study the interplay between the endogenous immune response and OV we profiled tumors from immunocompetent intracranial models of medulloblastoma and glioblastoma treated with measles virus (MV) and retrovirus (Toca-511), using single-cell and bulk-RNA sequencing. For both models, we assayed specimens from two treatment groups, a mid-treatment group where mice were sacrificed upon observation of treatment response, and a post-treatment group where treatment-resistant mice were sacrificed when they had succumbed to their disease. As controls, we included a cohort treated with heat-inactivated virus and a cohort treated with PBS. Both MV and Toca-511 OV therapies significantly improve survival compared to controls. From each of the MV and Toca-511 treatment/control groups, 3 mice per group were profiled via RNA sequencing. Additionally, tumors from 5 mice treated with MV alone and 4 mice treated with MV and anti-PD1 immune-checkpoint blockade (ICB) were subjected to single-cell RNA sequencing (scRNA-seq). ScRNA-seq generated 38,491 cells after filtering for quality control and successfully captured both endogenous and viral RNAs. We found that in samples treated with both OV and ICB there were higher rates of virally infected cells, depletion of M2-polarized myeloid infiltrates, and depletion of endothelial cells, compared to controls. Comparing virally infected tumor cells to non-infected controls we observed a down-regulation of translation initiation-complex genes and an upregulation of markers of oxidative phosphorylation. Infected cells from treatment-resistant tumors upregulate antigen presentation and myeloid chemotaxis genes. These studies show that OV enhances survival and anti-brain-tumor immunity. They support MV and ICB as potentially being synergistic. They suggest translation control and perturbation of the myeloid compartment as strategies for enhancing intracellular MV proliferation and infection efficiency, respectively.
format Online
Article
Text
id pubmed-10259983
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-102599832023-06-13 IMMU-09. DISSECTING THE INTERPLAY BETWEEN THE ENDOGENOUS IMMUNE RESPONSE AND ONCOLYTIC VIRUS THERAPY IN PEDIATRIC BRAIN TUMORS Hoare, Owen Jung, Jangham Inagaki, Akihito Yu, Bohyeon Collins, Sara Chuntova, Polly Barcova, Maria Patel, Trishna Kasahara, Noriyuki Müller, Sabine Diaz, Aaron Neuro Oncol Final Category: Immunology/Immunotherapy - IMMU Oncolytic virus (OV) elicits an antitumor immune response in addition to tumor-cell killing. However, it is unknown if a pre-existing antitumor immune response aids or hinders OV therapy. To study the interplay between the endogenous immune response and OV we profiled tumors from immunocompetent intracranial models of medulloblastoma and glioblastoma treated with measles virus (MV) and retrovirus (Toca-511), using single-cell and bulk-RNA sequencing. For both models, we assayed specimens from two treatment groups, a mid-treatment group where mice were sacrificed upon observation of treatment response, and a post-treatment group where treatment-resistant mice were sacrificed when they had succumbed to their disease. As controls, we included a cohort treated with heat-inactivated virus and a cohort treated with PBS. Both MV and Toca-511 OV therapies significantly improve survival compared to controls. From each of the MV and Toca-511 treatment/control groups, 3 mice per group were profiled via RNA sequencing. Additionally, tumors from 5 mice treated with MV alone and 4 mice treated with MV and anti-PD1 immune-checkpoint blockade (ICB) were subjected to single-cell RNA sequencing (scRNA-seq). ScRNA-seq generated 38,491 cells after filtering for quality control and successfully captured both endogenous and viral RNAs. We found that in samples treated with both OV and ICB there were higher rates of virally infected cells, depletion of M2-polarized myeloid infiltrates, and depletion of endothelial cells, compared to controls. Comparing virally infected tumor cells to non-infected controls we observed a down-regulation of translation initiation-complex genes and an upregulation of markers of oxidative phosphorylation. Infected cells from treatment-resistant tumors upregulate antigen presentation and myeloid chemotaxis genes. These studies show that OV enhances survival and anti-brain-tumor immunity. They support MV and ICB as potentially being synergistic. They suggest translation control and perturbation of the myeloid compartment as strategies for enhancing intracellular MV proliferation and infection efficiency, respectively. Oxford University Press 2023-06-12 /pmc/articles/PMC10259983/ http://dx.doi.org/10.1093/neuonc/noad073.196 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Final Category: Immunology/Immunotherapy - IMMU
Hoare, Owen
Jung, Jangham
Inagaki, Akihito
Yu, Bohyeon
Collins, Sara
Chuntova, Polly
Barcova, Maria
Patel, Trishna
Kasahara, Noriyuki
Müller, Sabine
Diaz, Aaron
IMMU-09. DISSECTING THE INTERPLAY BETWEEN THE ENDOGENOUS IMMUNE RESPONSE AND ONCOLYTIC VIRUS THERAPY IN PEDIATRIC BRAIN TUMORS
title IMMU-09. DISSECTING THE INTERPLAY BETWEEN THE ENDOGENOUS IMMUNE RESPONSE AND ONCOLYTIC VIRUS THERAPY IN PEDIATRIC BRAIN TUMORS
title_full IMMU-09. DISSECTING THE INTERPLAY BETWEEN THE ENDOGENOUS IMMUNE RESPONSE AND ONCOLYTIC VIRUS THERAPY IN PEDIATRIC BRAIN TUMORS
title_fullStr IMMU-09. DISSECTING THE INTERPLAY BETWEEN THE ENDOGENOUS IMMUNE RESPONSE AND ONCOLYTIC VIRUS THERAPY IN PEDIATRIC BRAIN TUMORS
title_full_unstemmed IMMU-09. DISSECTING THE INTERPLAY BETWEEN THE ENDOGENOUS IMMUNE RESPONSE AND ONCOLYTIC VIRUS THERAPY IN PEDIATRIC BRAIN TUMORS
title_short IMMU-09. DISSECTING THE INTERPLAY BETWEEN THE ENDOGENOUS IMMUNE RESPONSE AND ONCOLYTIC VIRUS THERAPY IN PEDIATRIC BRAIN TUMORS
title_sort immu-09. dissecting the interplay between the endogenous immune response and oncolytic virus therapy in pediatric brain tumors
topic Final Category: Immunology/Immunotherapy - IMMU
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10259983/
http://dx.doi.org/10.1093/neuonc/noad073.196
work_keys_str_mv AT hoareowen immu09dissectingtheinterplaybetweentheendogenousimmuneresponseandoncolyticvirustherapyinpediatricbraintumors
AT jungjangham immu09dissectingtheinterplaybetweentheendogenousimmuneresponseandoncolyticvirustherapyinpediatricbraintumors
AT inagakiakihito immu09dissectingtheinterplaybetweentheendogenousimmuneresponseandoncolyticvirustherapyinpediatricbraintumors
AT yubohyeon immu09dissectingtheinterplaybetweentheendogenousimmuneresponseandoncolyticvirustherapyinpediatricbraintumors
AT collinssara immu09dissectingtheinterplaybetweentheendogenousimmuneresponseandoncolyticvirustherapyinpediatricbraintumors
AT chuntovapolly immu09dissectingtheinterplaybetweentheendogenousimmuneresponseandoncolyticvirustherapyinpediatricbraintumors
AT barcovamaria immu09dissectingtheinterplaybetweentheendogenousimmuneresponseandoncolyticvirustherapyinpediatricbraintumors
AT pateltrishna immu09dissectingtheinterplaybetweentheendogenousimmuneresponseandoncolyticvirustherapyinpediatricbraintumors
AT kasaharanoriyuki immu09dissectingtheinterplaybetweentheendogenousimmuneresponseandoncolyticvirustherapyinpediatricbraintumors
AT mullersabine immu09dissectingtheinterplaybetweentheendogenousimmuneresponseandoncolyticvirustherapyinpediatricbraintumors
AT diazaaron immu09dissectingtheinterplaybetweentheendogenousimmuneresponseandoncolyticvirustherapyinpediatricbraintumors